A role for the androgen-receptor in clinically localized and advanced prostate cancer
A role for the androgen-receptor in clinically localized and advanced prostate cancer
复制标题
DOI：
10.1016/j.beem.2008.01.009
复制
发表时间：
2008-04-01
影响因子：
7.4
通讯作者：
Mohler, James L.
中科院分区：
文献类型：
--
作者：
Mohler, James L.
早期使用冷冻前列腺组织进行的雄激素受体（AR）表达研究以及后来使用存档标本进行的研究得出了以下共识：配体稳定的AR是细胞核，AR表达在良性上皮和间质中相似，AR表达在分泌上皮中比基底细胞更高，并且AR表达在前列腺癌（CaP）中比在良性前列腺增生（BPH）中更多变。AR表达的准确测量在技术上仍然具有挑战性，但对于评估AR与临床CaP的相关性是必要的。最近的研究表明，在上皮和间质中的AR表达可能是临床局部CaP的预后，AR表达可能在Cap死亡率的种族差异中发挥作用，并预测对雄激素剥夺治疗的反应。高水平的AR和AR调节的基因表达表明AR在去势复发性CaP的生长调节中起着重要作用。新的治疗致命表型的帽子需要更好地了解AR反式激活在雄激素剥夺治疗。
Earlier studies of androgen-receptor (AR) expression using frozen prostate tissue, and later studies using archived specimens, produced the consensus that ligand-stabilized AR is nuclear, AR expression is similar in benign epithelia and stroma, AR expression is greater in secretory epithelia than basal cells, and AR expression is more variable in prostate cancer (CaP) than in benign prostatic hyperplasia (BPH). Accurate measurement of AR expression remains technically challenging but necessary to evaluate the relevance of AR to clinical CaP. Recent studies demonstrated that AR expression in epithelia and stroma may be prognostic in clinically localized CaP and AR expression may play a role in racial differences in Cap mortality and predict response to androgen deprivation therapy. High levels of AR and AR-regulated gene expression indicate a central role for AR in growth regulation of castration-recurrent CaP. New treatments for the lethal phenotype of Cap require better understanding of AR transactivation during androgen deprivation therapy.